Safety Study of Nivolumab for Selected Advanced Malignancies in India - Nivolumab study
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2019 Planned primary completion date changed from 30 Dec 2018 to 1 Sep 2019.
- 12 Mar 2018 Planned End Date changed from 21 Apr 2020 to 29 Apr 2020.